Sector News

Shire to split operations in two

January 16, 2018
Life sciences

Shire has unveiled plans to split its operations into two separate entities – a neuroscience division and rare diseases one, and will later decide whether they should be listed independently.

The proposal follows the first stage of a strategic review of the firm’s neuroscience business, which concluded that it “warrants additional focus and investment”.

According to the Dublin, Ireland-headquartered group, the move will see each division benefit from “a sharper management focus, greater strategic clarity, and an increased ability to deploy resources to key growth priorities”.

Operational performance metrics of each division should be reported separately from the first quarter of this year.

Meanwhile, the second stage of the review will further evaluate all strategic alternatives, including the merits of an independent listing for each of the two divisions.

“Our new Rare Disease and Neuroscience Divisions will be well positioned for growth, profitability, innovation, and serving the needs of patients,” said Shire chief executive Flemming Ornskov.

The firm also said it has a promising late stage pipeline with fifteen programs currently in Phase III, and that it expects total revenues to reach $17-18 billion by 2020.

By Selina McKee

Source: Pharma Times

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend